Literature DB >> 8438097

Bronchial hyperresponsiveness in patients recovering from acute severe asthma.

M K Whyte1, N B Choudry, P W Ind.   

Abstract

Bronchial hyperresponsiveness is widely recognized as a marker of airway inflammation in asthma. The degree of bronchial hyperresponsiveness following acute severe attacks of asthma and the time course of its recovery has not previously been studied. Bronchial responsiveness to histamine was measured in 18 unselected patients admitted to hospital because of acute severe asthma, during their acute admission, and geometric mean PD20 histamine was 0.08 (range 0.02-0.32) mumol. In nine patients, further measurements were performed at 3-4 and 12 weeks following discharge. Geometric mean PD20 histamine was 0.09 mumol acutely, 0.23 mumol at 3-4 weeks (n = 9, p = 0.05 by analysis of variance) and 0.59 mumol at 12 weeks (n = 8, P = 0.04). For the eight patients studied at 12 weeks, a mean 10.3-fold increase in PD20 was shown, with no suggestion of a maximum effect having been achieved. In contrast, spirometry had returned to the normal range by 4 weeks. The dissociation between improvement in bronchial hyperresponsiveness and spirometry is of interest. The delayed reduction in hyperresponsiveness may have important clinical implications for the duration of anti-inflammatory corticosteroid treatment following acute severe asthma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8438097     DOI: 10.1016/s0954-6111(05)80310-5

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

1.  Usefulness of asthma predictive index in ascertaining asthma status of children using medical records: An explorative study.

Authors:  C-I Wi; E A Krusemark; G Voge; S Sohn; H Liu; E Ryu; M A Park; J A Castro-Rodriguez; Y J Juhn
Journal:  Allergy       Date:  2018-02-07       Impact factor: 13.146

2.  Relationship between the inflammatory infiltrate in bronchial biopsy specimens and clinical severity of asthma in patients treated with inhaled steroids.

Authors:  J K Sont; J Han; J M van Krieken; C E Evertse; R Hooijer; L N Willems; P J Sterk
Journal:  Thorax       Date:  1996-05       Impact factor: 9.139

3.  IL-12-STAT4-IFN-gamma axis is a key downstream pathway in the development of IL-13-mediated asthma phenotypes in a Th2 type asthma model.

Authors:  You-Sun Kim; Seng-Jin Choi; Jun-Pyo Choi; Seong Gyu Jeon; Sun -Young Oh; Byung-Jae Lee; Yong Song Gho; Chun Geun Lee; Zhou Zhu; Jack A Elias; Yoon-Keun Kim
Journal:  Exp Mol Med       Date:  2010-08-31       Impact factor: 8.718

4.  Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.

Authors:  Z Zhu; R J Homer; Z Wang; Q Chen; G P Geba; J Wang; Y Zhang; J A Elias
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

5.  Distribution of immunocompetent cells in the bronchial wall of clinically healthy subjects showing bronchial hyperresponsiveness.

Authors:  C Power; S Sreenan; B Hurson; C Burke; L W Poulter
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

6.  Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness.

Authors:  O Einarsson; G P Geba; Z Zhu; M Landry; J A Elias
Journal:  J Clin Invest       Date:  1996-02-15       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.